The Use of Mushroom Preparations in Malignancies

Mushroom preparations are used widely in Asia as complements to conventional cancer
therapies, and have been used so for many years. In the last ten years they have become more widely
available in the western world. Various medications derived from different mushrooms, especially
Coriolus, Shitake, Reishi and Maitake mushrooms, have been studied. Two other combination agents,
active hexose correlated compound (AHCC), and MGN-3 deserve mention, particularly because of their
widespread use.

Physiological Effects
Mushrooms are commonly thought of as immunopotentiating agents. Their effects, however,
extend far wider than only the immunological system.
Their effects on the immune system are thought to be mediated through B-D glucan linkages in
their chemical structure. These are monosaccharide polymers. These monosaccharides can also be
linked to proteins, where they are then termed proteoglycans. Numerous immunologically related
activites have been confirmed with the use of mushroom preparations, including dendritic cell
maturation and activation, macrophage and phagocytic activation, NK cell activation, improvement of
the CD4/CD8 and Th1/Th2 ratios, and increased production of various cytokines, including interleukins
1, 2, 6, 8, interferons and tumor necrosis factor (1,2,3). These could all be beneficial in patients with
malignancies
In addition to their direct immune effects, mushroom preparations have been shown to have other effects
that could be clinically beneficial for cancer patients. These include inhibiting important transcription
factors that are antiapoptotic, such as NFkB, AP-1, and urokinase plasminogen activator (4,5,6).
Mushroom preparations have been shown to have antioxidant properties, have been able to mimic the
free scavenging effects of superoxide dismutase and can increase glutathione peroxidase activity (7,8,9).
Other activites include the decreasing of myelosuppression associated with chemotherapy in a murine
model, increasing hematopoesis (10), and the overcoming of resistance of tumor cells to complement
mediated cytotoxicity (11). Monoclonal antibodies work through various mechanisms, including having
direct tumor cytotoxic effects, through the activation and enabling of NK cells, and through complement
mediated cytotoxicity. Studies have suggested that the combination of a B-glucan substance, such as
found in mushrooms, can enhance the effect of monoclonal antibodies . Cheung has studied the effect
of combining B-glucans with monoclonal antibodies in numerous tumor cell lines and has found a very
significant enhancement of cytotoxicity (12,13). This appears to occur by overcoming tumor cell
resistance to opsonization with the C3. With the burgeoning interest and increasing use of monoclonal
antibodies, this property of mushrooms has potential importance.
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Mushroom preparations, in addition to being investigated in cell culture, in vitro and animal
studies, have been relatively widely studied in humans (compared to other integrative treatment
modalities), including randomized clinical studies, with promising results. This is true especially for the
preparations from Coriolus mushrooms, known as PSK or Krestin, and PSP. Most of the following
discussion will be centered on these medications.

Clinical Trials with Coriolus Preparations
Medicines derived from the Coriolus Versicolor mushroom have been studied in patients with
colorectal malignancies. Ohwada studied patients with Stage II or III colorectal cancer, comparing a
group treated with surgery and chemotherapy versus a group which also received PSK produced from
Coriolus. After three years they found a mild benefit in disease free survival (80.6 vs 68.7 p=0.02), and
overall survival (87.3 vs 80.6 p= 0.024) in the PSK group. In stage III patients the three-year overall
survival was improved (83 vs 59.3 p= 0.02). The treatment group also showed a decrease in distant
metastases (0.05), particularly to the lung (0.01). (14)
Ito studied patients with Dukes C colorectal tumors, comparing 440 patients treated with either 5
FU and PSK, or with 5 FU alone. He found a statistical difference in cancer related deaths ( 49 vs. 37,
p= 0.19) in the treated group (15).Other studies (16, 17) have supported these positive findings.
PSK has been extensively studied in gastric cancer, which is a very common malignancy in
Asian countries. Kaibara compared a group with stage IV gastric cancer, comparing conventional chemo
and surgical treatment with or without PSK. Two year survival was improved (34 vs. 15% p<0.05)(18).
Numerous studies by the group of Kodama, Kano et al. confirmed significant benefit from the addition
of PSK to the usual treatment regimens (19,20). A study by Nakazoto, published in the Lancet, showed a
slight benefit in 5 year disease free and survival rate (70.7 vs. 59.4% p=0.047, 73 vs. 60% p=0.044), in
the group treated with standard treatment and PSK versus the group without PSK(21).
Ogoshi compared patients with esophageal cancer treated with conventional treatment with or
without chemotherapy, and found a non-statistically significant trend towards improvement in 5-year
survival. They found that the improved survival was noted especially in patients with the presence of
high levels of immunosuppressive substances sialic acid and alpha i-antichymotrypsin (22,23).
Hayakawa compared patients with non-small cell lung cancer who were treated with radiation
therapy with or without PSK. Five year survival rates were significantly improved in the PSK group in
stages I, II and III (39 vs 17, 26 vs 8%)(24).
Studies have also been reported in breast cancer and leukemias (see ref 1 for summary).

Studies with Other Mushroom Preparations
While the bulk of research has been with Coriolus derived medications, some provocative studies
have looked at AHCC and MGN-3. MGN-3, which is a rice bran compound that is modified by
mushroom enzymes, has shown very impressive results regarding augmentation of NK activity. Most of
the studies have been done by a single group, so caution should be applied in the reproducibility of this
data. The compound AHCC has been studied in numerous situations. A study in patients with
hepatocellular carcinoma showed significant benefit when AHCC was employed after surgical resection
(25). AHCC has been combined with genistein in a product called Genistein Combined Polysaccharide
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(GCP). The presence of the isoflavone genistein might be helpful in patients with prostate cancer, both
because of its estrogen like effects, as well as effects on protein kinase C. A provocative case report
discussed the use of this product in a patient with prostate cancer. This patient had biopsy proven
prostate cancer with a PSA of 19.7. He was treated for six weeks with GCP prior to radical
prostatectomy. The PSA decreased to 4.2 and the surgical specimen showed no evidence of tumor (26).
Other mushroom preparations are of interest and have been studied in preliminary ways.
Maitake mushrooms, particularly the D fraction, have been studied in animals and in vitro (27,28),
showing results on relevant aspects of the immune system. Kodama used Maitake preparations, without
chemotherapy, in patients with Stage IV tumors in different sites (lung, liver, breast), and found both
laboratory and clinical evidence of improvement, including some patients with radiological evidence of
tumor shrinkage and regression (29). Sliva (30,31) has performed a series of interesting experiments
with Reishi mushrooms, showing beneficial effects on transcription factors as well as inhibiting
migration of highly invasive prostate and breast cancer cells.
When patients are administered chemotherapy, common effects include immunosuppression, as
well as an augmented production of transcription factors, such as NFkB and AP-1, which stimulate
tumor growth and chemoresistance by various mechanisms. As noted above, mushroom preparations
can potentially alleviate the immunosuppression, myelosuppression and transcription factor production
that occurs in patients undergoing chemotherapy. Therefore their use alongside conventional
chemotherapy can be expected to be beneficial. This appears to be confirmed in the numerous studies
cited above.

Conclusions
In summary, mushroom preparations have been shown to have a wide range of physiological
effects which are likely to be beneficial in patients with malignancies. These extend beyond immune
system stimulation to additional effects on transcription factors, antioxidant effects, and inhibiting
invasion. There are also intriguing studies combining their use with monoclonal antibodies. Clinical
studies in a diverse range of tumors have shown mild to moderate additive benefits when combined with
conventional treatment regimens. Although these preparations have been shown to have antioxidant
effects alongside their other actions, no evidence for interference with chemotherapy or radiation
therapy exists. Indeed the studies suggest the opposite; an augmentation of their benefit.
Numerous mushroom preparations are available, including combinations of different
mushrooms, and products containing isolated B-glucans. The most widely studied mushrooms are those
prepared from Coriolus Versicolor, where in addition to cell line, animal, in vitro and in vivo studies,
numerous randomized clinical studies have been completed. Other mushrooms, especially Maitake and
Reishi, have a more limited evidence base. Two unusual products, AHCC and MGN-3 are used and
marketed widely, but have an interesting, but clearly smaller evidence base. Some products contain
combinations of different mushrooms. Individual mushrooms have overlapping, but unique
compositions and properties. These combination products might show synergistic actions, but have not
been studied. The side effect profile of these preparations is minimal. Costs at the present time are not,
however, insubstantial. A one-month course can cost between $100-200.
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